Table 1.

Location of Evaluation, Primary Diagnosis, and Therapeutic Agents for Cardio-Oncology Consultations

Location of cardio-oncology evaluation and referrals with a documented diagnosis

Outpatient referral: 142 (64.0)

Inpatient consultation: 80 (36.0)

Reason for referral∗

Arrhythmia: 38 (17.0)

Cardiovascular risk factor management: 36 (16.0)

Decreased ejection fraction: 30 (13.0)

Decompensated heart failure: 26 (12.0)

Chest pain: 29 (13.0)

Edema: 18 (8.0)

Pre-chemotherapy assessment: 16 (7.0)

Acute myocardial infarction: 12 (5.0)

Unstable angina: 8 (3.0)

Hypertension: 6 (3.0)

Myocarditis: 4 (2.0)

Other: 23 (10.0)

Therapeutic agent†

Taxanes: 86 (27.0)

Anthracycline: 70 (22.0)

Platinum compounds: 70 (22.0)

Cytoxan (cyclophosphamide for injection): 64 (20.0)

Other alkylating agents: 27 (9.0)

Vinca alkaloids: 37 (11.6)

Anti-Her 2: 31 (10.0)

Anti-vascular endothelial growth factor: 18 (6.0)

Anti-CD20: 29 (9.0)

Checkpoint inhibitor: 18 (6.0)

Other: 80 (25.0)

Values are n (%).

^∗Patients may have had more than 1 diagnosis.

^†Patients many patients received more than 1 chemotherapy agent.